Home  >  Why Agilent

Why Agilent

Who We Are

Agilent delivers trusted answers and insights to advance the quality of life. Our laboratory instruments and technologies help scientists further disease research, develop advanced therapies, and ensure our water, food, air, and fuels are clean. The discoveries we enable make the world a better place to live.

  • Markets we serve
  • Markets we serve
  • Industry leading capabilities
  • The Agilent Difference

Agilent serves large, attractive markets with a $80B opportunity, growing 4-6%

Pharma
Pharma & BioPharma
$25BTAM*
Market Position
#2
Chemicals
CHEMICAL & ADVANCED MATERIALS
$8BTAM*
Market Position
#1
Clinical
CLINICAL & DIAGNOSTICS
$20BTAM*
Market Position
#2-3
Academia
ACADEMIC & GOVERNMENT
$14BTAM*
Market Position
#2
Food
Food
$6BTAM*
Market Position
#2
Environmental
ENVIRONMENTAL & FORENSICS
$7BTAM*
Market Position
#1

Agilent provides critical tools and capabilites that help our customers address some of humanity’s biggest challenges including disease detection and therapeutics, environmental health, and food safety.

*TAM = Total Available Market. Market size per Company estimates

Agilent has market leadership position in key analytical and diagnostic technologies

Life Science Tools
Life Sciences & Diagnostics Markets

Liquid Chromatography (LC)
LC Mass Spectrometry (LCMS)
CDMO
Cell Analysis
Genomics
Pathology
Companion Diagnostics

FY24 Revenue*
$2.5B
CrossLab
Agilent CrossLab

Analytical Consumables
Services
Software
Lab Automation

FY24 Revenue*
$2.7B
Clinical
Applied Markets

Gas Chromatography (GC)
GC Mass Spectrometry (GCMS)
Spectroscopy
Vacuum
Certified Pre-owned Instruments

FY24 Revenue*
$1.3B

Agilent’s trusted measurements and workflow solutions enable customers in analytical, research and diagnostics laboratories achieve superior scientific and economic outcomes


Agilent represents a differentiated investment opportunity with a track record of consistent results

Attractive returns

  • History of consistently outgrowing the markets
  • Superior profitability and cash-generation

TECHNOLOGY LEADER IN ATTRACTIVE MARKETS WITH SECULAR GROWTH TRENDS

  • Leader in life science and diagnostic tools
  • End markets focused on improving human condition and have long-term secular growth drivers
  • Sustained R&D investment and an established leading innovator in the industry

Strategic Capital Deployment

  • Focus on M&A to increase exposure in faster-growing markets and geographies
  • Growing cash dividends
  • Consistent return of excess cash to shareholder
Revenue Growth
6% CAGR
Margin Growth(1)
+290 bps
EPS Growth(1)
13% CAGR

(1) Operating Margin & EPS presented on a non - GAAP basis, reconciliations to closest GAAP equivalent provided in financial summary.